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Routine mass immunization programs have contributed greatly 
to the control of infectious diseases and to the improvement of 
the health of populations. Over the last decades, the rise of anti-
vaccination movements has threatened the advances made in this 
field to the point that vaccination coverage rates have decreased 
and outbreaks of vaccine-preventable diseases have resurfaced. 
One of the critical points of the immunization debate revolves 
around the level of risk attributable to vaccination, namely 
the possibility of experiencing serious and possibly irrevers-
ible adverse events. Unfortunately, the knowledge about adverse 
events, especially rare ones, is usually incomplete at best and the 
attribution of a causal relationship with vaccinations is subject 
to significant uncertainties. The aim of this paper is to provide a 
narrative review of seven rare or very rare adverse events: hypo-
tonic hyporesponsive episode, multiple sclerosis, apnea in pre-
term newborns, Guillain-Barré syndrome, vasculitides, arthritis/
arthralgia, immune thrombocytopenic purpura. We have selected 
these adverse events based on our experience of questions asked 
by health care workers involved in vaccination services. Infor-
mation on the chosen adverse events was retrieved from Medline 
using appropriate search terms. The review is in the form of ques-
tions and answers for each adverse event, with a view to provid-
ing useful and actionable concepts while not ignoring the uncer-
tainties that remain. We also highlight in the conclusion possible 
future improvements to adverse event detection and assessment 
that could help identify individuals at higher risk against the 
probable future backdrop of ever-greater abandonment of com-
pulsory vaccination policies.
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Summary
Introduction
In the last 10 years, great advances have been made in 
developing and introducing new vaccines and expanding 
immunization programs. More people than ever before 
are being vaccinated and access and use of vaccines by 
age groups other than infants is expanding. As a result 
of immunization combined with other health care and 
development interventions – including improved access 
to clean water and sanitation, better hygiene and educa-
tion – the annual number of deaths among children un-
der five years of age fell from an estimated 9.6 million 
in 2000 to 7.6 million in 2010, despite an increase in the 
number of children born each year [1].
According to World Health Organization (WHO) da-
ta, vaccination prevents 2-3 million deaths every year 
worldwide. At the same time, WHO warns that globally 
22 million newborns do not receive basic immunization; 
among them there are 700,000 newborns belonging to 
the WHO European Region. Vaccination is perceived as 
unsafe and unnecessary by a growing number of parents 
in large part because diseases that were once the cause 
of many outbreaks and loss of health and life are now 
rarely seen, because they have been prevented by vac-
cines. In this perspective, a rare potential for vaccine-
induced harm can loom large when people no longer 
experience the targeted disease, a case of vaccines being 
the victims of their own success. In fact anti-vaccination 
movements have been implicated in lowered vaccine ac-
ceptance rates and in the increase in vaccine-preventable 
disease outbreaks and epidemics. In large part, this is 
caused by mistrust in the medical system and by fear of 
adverse events (AEs) that doctors are unwilling to talk 
about. On the contrary, research has shown that exposure 
to scientific proof can be effective in boosting patients’ 
knowledge; in the USA, the Centers for Disease Con-
trol and Prevention (CDC) published information aim-
ing to educate the reader and dispel the most widespread 
myths [2-5].
In spite of the fact that vaccines currently used in immu-
nization programs are safe, like all medicinal products 
they have potential health risks and can cause adverse 
events, defined as harmful and unintended effects fol-
lowing the use of a medicinal substance [6].
Regarding vaccines, an Adverse Event Following Im-
munization (AEFI) is any harmful clinical event that 
occurs after vaccine administration and that does not 
necessarily have a causal relationship with vaccine use. 
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In this context an AEFI could be an unintentional unfa-
vorable sign, a laboratory test anomaly, a symptom or a 
disease [7].
It is important to point out that in this definition of AEFI, 
only a temporal association is considered and no causal 
relationship is implied; indeed, much of the assessment 
of AEFIs is devoted to ascertaining whether a causal 
relationship actually exists (under different degrees of 
likelihood, i.e. certainly, probably, possibly related or 
unrelated).
The scientific knowledge about AEFIs is limited because 
their notification is frequently overlooked by physicians 
(under-notification) and because the available adverse 
event data frequently show only temporal relationships 
between vaccination and the onset of an AEFI. Indeed 
the establishment of causality is challenging and re-
quires much time and labor. In fact, the largest review of 
adverse events to date, published in 2012 by the Institute 
of Medicine of the USA (IOM), explains in the Preface 
that in the majority of cases, available scientific informa-
tion was not sufficient to conclude whether a particular 
vaccine caused a specific rare AEFI [8, 9]. One of the 
reasons is that even very large epidemiologic studies 
may not be able to detect or rule out rare (or very rare) 
AEFIs. An AEFI is conventionally considered rare if it 
occurs in < 1/1000 but > 1/10000 individuals (very rare 
if < 1/10000 individuals). There is a residual category 
of AEFI for which frequency is unknown because they 
were spontaneously reported after the vaccine was mar-
keted and therefore the denominator required to com-
pute frequency was unavailable [10].
There are many elements to be considered in assessing 
the risk-benefit balance of vaccine administration. First 
of all, the advantages of vaccine administration have to 
be taken into account, in terms of benefits (protection) 
afforded by each dose administered.
Next, the likelihood of contracting the disease must be 
considered, which is itself related to the incidence of the 
disease, to the vaccine coverage rate in the population 
and to other factors that can increase risk, for example 
exposure to a case, occupational risk or travels to highly 
endemic areas.
A thorough assessment of the frequency, severity, and 
causal relation of AEs (and their complications) is al-
so necessary, especially for Serious Adverse Events 
(SAEs) [11]. A SAE is any adverse event that either re-
sults in death, or is life-threatening, or requires inpatient 
hospitalization or causes prolongation of existing hospi-
talization, or results in persistent or significant disabil-
ity/incapacity, or is a congenital anomaly/birth defect, or 
requires intervention to prevent permanent impairment 
or damage [12].
The need to answer questions from patients and health 
care workers (HCWs) and to choose whether to vac-
cinate an individual or not, based on a risk-benefit as-
sessment that takes into account the susceptibility of the 
individual (a form of personalized medicine), forms the 
basis of our review that aims to provide actionable an-
swers to doubts about a selection of rare, very rare or of 
unknown frequency adverse events.
We focused on the issues regarding risk assessment, risk 
communication and risk management for seven AEFIs:
• Hypotonic Hyporesponsive Episode (HHE);
• Multiple Sclerosis (MS);
• Apnea in the pre-term newborn (APTN);
• Guillain-Barré Syndrome (GBS);
• Vasculitides;
• Arthritis/Arthralgia (AA);
• Immune Thrombocytopenic Purpura (ITP).
Methods and search results
We performed a literature search on Medline using Pub-
Med up to August 26th 2016. We applied neither language 
nor date of publication restrictions and we performed the 
search using the following search terms individually and 
in combination: vaccin*; immuniz*; immunis*; throm-
bocytopenia; apnea; hypotonic hyporesponsive; Guillain 
Barré; multiple sclerosis; arthritis; arthralgia; vasculitis. 
Tab. I. Search strategy and results.
Search item Search terms (S)
Number retrieved 
(Numbers in brackets 
used in combined 
searches)
S1 Vaccin* (323853)
S2 Immuniz* (165606)
S3 Immunis* (11117)
S4 Thrombocytopenia (64342)
S5 Apnea (46708)
S6
Hypotonic 
hyporesponsive
47
S7 Guillain Barré (8165)
S8 Multiple Sclerosis (70531)
S9 Arthritis (281729)
S10 Arthralgia (13873)
S11 Vasculitis (97428)
S12 S1 AND S4 644
S13 S1 AND S5 125
S14 S1 AND S7 615
S15 S1 AND S8 999
S16 S1 AND S9 2057
S17 S1 AND S10 223
S18 S1 AND S11 533
S19 S2 AND S4 878
S20 S2 AND S5 82
S21 S2 AND S7 345
S22 S2 AND S8 1333
S23 S2 AND S9 2791
S24 S2 AND S10 63
S25 S2 AND S11 433
S26 S3 AND S4 42
S27 S3 AND S5 20
S28 S3 AND S7 33
S29 S3 AND S8 59
S30 S3 AND S9 184
S31 S3 AND S10 9
S32 S3 AND S11 19
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We also used the report of the Institute of Medicine [8] 
for reference.
We have chosen to answer for each AEFI the following 
frequently asked questions (FAQs) based on the requests 
for information that HCWs routinely ask:
• definition and incidence of the adverse event;
• biological plausibility based on the existence of 
pathophysiological mechanisms that lead to adverse 
event onset, and causality assessment;
• risk factors for AEFI onset after vaccination;
• types of vaccines possibly associated with the ad-
verse event and AE management;
• special considerations in vaccine administration to 
patients:
- who experienced the AEFI following a previous 
immunization.
- who suffer from or have had episodes of the dis-
ease in question (In this context we use the term 
“disease” when the AEFI corresponds to a well-
recognized disease and we consider the disease to 
be a possible risk factor for its own exacerbation 
after immunization).
For the AEFI, we used validated case definitions where 
available and, as regards pathophysiology, we reported 
the main hypotheses according to current scientific 
knowledge. Selection of information on the vaccines po-
tentially implicated in the various AEFIs, on the main 
risk factors and on the recommendations for immuni-
zation of individuals who previously experienced the 
AEFI, was also performed based on the reports available 
from the literature. The results obtained from the search 
strategy are shown in Table I.
Frequently Asked Questions (FAQs)
Hypotonic Hyporesponsive Episode (HHE)
How is a case of HHE defined and how frequent is it?
HHE is a clinical condition which has the following 
features: reduced muscle tone, hyporesponsiveness and 
change of skin color, in the absence of cardiologic (par-
ticularly of heart rhythm), electroencephalographic and 
glycemic alterations [13]. Apart from the clinical triad of 
signs there are no further investigations helpful in con-
firming the diagnosis of HHE [14-16]. The reported rates 
following a whole cell pertussis vaccine ranges from 0 
- 291 per 100,000 doses [17, 18]. The median time to on-
set of signs after immunization is 3–4 h but ranges from 
immediately to 48 h post-immunization, while the me-
dian duration of the triad signs is 6–30 min [16] (Fig. 1).
What are the pathophysiological mechanisms under-
lying HHE?
Pathophysiology of HHE is currently unknown. It was 
hypothesized in the first studies about this AE, that the 
pathophysiological mechanism could be an exaggerated 
vagal response, but the timing of onset of HHE and the 
lack of ECG, EEG and glycemic alterations led to refut-
ing this hypothesis and, at the present time, no new hy-
potheses have been put forward. The main efforts have 
been put into defining correctly HHE in order to avoid 
mistakes in diagnosis and notification [16, 19, 20].
Which are the vaccines associated with HHE onset?
The first cases were reported in children under 5 years 
of age following administration of whole-cell pertussis 
vaccine [15, 16]. Over the last 20 years, cases of HHE 
have been reported following administration of diphthe-
ria, tetanus, H. influenzae B, Hepatitis B Virus, 13-valent 
pneumococcal, acellular pertussis vaccines. In the latter 
case, the frequency appears to be lower than with the 
whole-cell vaccine [13, 16, 21].
What are the risk factors for HHE and how can it be 
managed?
No risk factors have been identified and so there are no 
specific precautions to be taken.
According to studies based on the follow-up of HHE 
relying on parental reporting and neurodevelopmen-
tal testing, HHE is a self-limiting event without long-
term sequelae [16], so it is important to reassure the 
parents that it is an event that does not lead to com-
plications.
What is the recommended action regarding immuni-
zation in case of a previous episode of HHE?
According to a recent Polish study, in a group of 49 
children who experienced HHE following diphtheria-
tetanus-whole cell pertussis vaccination (DTwP), 2 
children experienced a second episode of HHE after 
a second consecutive dose of DTwP  [22]. According 
to this study, it seems that HHE can recur more fre-
quently in children who have already experienced it 
compared to the general population. In spite of this 
observation, no contraindications to subsequent vac-
cination exist for these children.
Fig. 1. Time frame of attribution of selected AEs to vaccination.
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Multiple Sclerosis (MS)
How is a case of MS defined and how frequent is it?
Multiple Sclerosis (MS) is an acquired chronic immune-
mediated inflammatory condition of the central nervous 
system (CNS), affecting both the brain and spinal cord. It 
is the most frequent cause of serious physical disability in 
working age people. The person affected by MS typically 
develops symptoms in their late 20s, experiencing visual 
and sensory disturbances, limb weakness, gait problems 
and symptoms which affect urinary and gastrointestinal 
tracts. The clinical course is often characterized at the 
beginning by a partial recovery, but over time MS tends 
to evolve toward increasing disability [23]. In 2007, glob-
ally, the median estimated prevalence of MS was 30 per 
100,000 while regionally, the median estimated prevalence 
of MS was greatest in Europe (80 per 100,000), followed 
by the Eastern Mediterranean (14.9), the Americas (8.3), 
the Western Pacific (5), South-East Asia (2.8) and Africa 
(0.3). The total estimated number of people diagnosed 
with MS was approximately 1.3 million [24].
What are the pathophysiological mechanisms under-
lying post-vaccination MS?
Pathophysiology of post-vaccination MS is uncertain. 
The first hypothesis was based on the discovery, in 1985, 
of a molecular mimicry phenomenon between Hepatitis 
B Virus (HBV) polymerase and myelin basic protein, but 
in light of subsequent research, today this association 
appears to be far less significant [25, 26]. Currently the 
most plausible mechanism seems to be hyperstimulation 
of the immune system that acts as an enhancer of a pre-
existing autoimmune vulnerability [27].
Which are the vaccines associated with MS onset?
According to a case-control study in France in a pediatric 
population, it was observed that in the three years follow-
ing HBV vaccination the odds for developing an MS flare 
were 1.5 but this result was not statistically (95%CI) signifi-
cant [28]. In a subsequent case-control study in California, a 
possible increase in central demyelination risk in the first 30 
days after any vaccination was reported in subjects under 50 
years of age. A trend towards an association of MS and any 
type of vaccination within 42 days (6 weeks) after immuni-
zation was identified (OR: 2.32; 95%CI: 1.18-4.57), but this 
result was obtained in a small sample of cases and cannot be 
generalized at the present time (Fig. 1). Moreover, since this 
association has not been observed in the longer term in the 
above study, it is hypothesized that vaccination could act as 
a trigger for underlying MS [27].
Which are the risk factors for MS and how do they 
affect immunization?
There are several risk factors (15-60 years of age, female 
gender, family history, Epstein Barr Virus infection, etc.) 
for MS but they do not affect routine immunization prac-
tice since the association between MS and vaccination 
has not been demonstrated in spite of numerous studies 
on this topic [8].
What is the recommended action regarding immuni-
zation in case of previous or ongoing acute episodes 
of MS?
Inactivated vaccines are generally considered safe while 
live ones can require further analyses of risk and benefit, 
especially for patients on immunosuppressive agents in 
whom usually live attenuated vaccines should be avoid-
ed. On the contrary, Varicella Zoster Virus (VZV) vacci-
nation is required before initiating treatment with certain 
disease modifying treatments, such as glucocorticoids, 
methotrexate and biologics [29]. Moreover, as far as tet-
anus vaccine is concerned, there is evidence that it can 
reduce the probability of MS relapse [30].
Apnea in pre-term newborns (APTN)
How is a case of APTN defined and how frequent is 
it?
An apneic episode is usually defined as a cessation of 
breathing for 20 seconds or longer or a shorter breathing 
pause accompanied by bradycardia (< 100 bpm), cyano-
sis or pallor [31].
It is a significant clinical problem manifested by an un-
stable respiratory rhythm reflecting the immaturity of 
respiratory control systems.  Anatomically the imma-
turity is manifested as decreased synaptic connections, 
decreased dendritic arborization and poor myelination. 
The condition should be considered a developmental 
disorder rather than a disease state because it resolves 
with maturation  [32]. All infants born at ≤  28 weeks’ 
gestation were diagnosed with apnea, while 85% of 
those born at 30 weeks and 20% of those born at 34 
weeks were diagnosed with apnea [31].
Regarding post-immunization APTN, some authors esti-
mate an incidence rate of post-immunization cardiores-
piratory events (apnea, bradycardia and/or desaturation) 
between 7 and 47% [33-35], whereas for apnea alone the 
incidence varies between 10 and 20% [36, 37].
What are the pathophysiological mechanisms under-
lying APTN?
Pathophysiological hypotheses are uncertain and not re-
lated to a specific vaccine or to adjuvants. An increase 
in systemic inflammatory response after immunization 
interacting with an immature nervous system in the pre-
term newborn has been postulated. In support of this 
hypothesis studies have shown that there is a temporal 
correlation between immunization and an increase in in-
terleukin 6 (IL-6) and C-reactive protein (CRP) [38-41].
Which are the vaccines associated with APTN onset?
Vaccines associated with APTN are: diphtheria-teta-
nus-whole cell pertussis, H.  influenzae b, Hepatitis B 
Virus, Inactivated Polio Virus, Meningococcal C con-
jugate (DTwP, DTwP-Hib, DTwP-Hib-HBV-IPV and 
MenC)  [34-37,  42,  43]. As far as pertussis vaccine is 
concerned, it has recently been shown that the incidence 
of APTN post-diphtheria-tetanus-acellular pertussis 
(DTaP) immunization is similar to the post-DTwP inci-
dence of APTN [44-46].
What are the risk factors for APTN and how do they 
affect immunization?
Several risk factors have been identified: age [35, 43, 44], 
weight [34, 37, 43], gestational age [44], previous mechani-
cal ventilation [34, 35], presence of chronic pulmonary pa-
thology [34], history of cardiorespiratory events [44, 46], 
pre-immunization apnea episodes [47]. Some studies have 
highlighted that the association between apnea and immu-
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nization is significant if immunization occurred before 67 
days of age, whereas significance disappears for immuniza-
tion after this time period [47, 48]. It is therefore advisable 
to perform cardiorespiratory monitoring after vaccination 
of all pre-term infants with risk factors [47].
What is the recommended action regarding immuni-
zation in case of previous episodes of APTN?
As with all preterm newborns, immunization is very im-
portant and should be performed according to chronolog-
ical age. If possible the first vaccination should be per-
formed before the discharge from the hospital [49-51].
It is advisable to perform cardiorespiratory monitoring 
after vaccination particularly for those who experienced 
pre-immunization apnea who are at 25-fold risk of devel-
oping post-immunization apnea compared to those who 
did not [47]. In order to avoid recurrent episodes in pre-
term infants who experienced post-immunization apnea, 
cardiorespiratory monitoring for at least 24 hours after 
vaccination is recommended [41] (Fig. 1). However, the 
episodes of post-vaccination apnea are self-limiting and 
do not cause long-term sequelae [44, 52] (Fig. 2).
Guillain-Barré Syndrome (GBS)
How is a case of GBS defined and how frequent is it?
Guillain-Barré syndrome (GBS) is a rare condition in 
which a person’s immune system attacks their peripheral 
nerves. The syndrome can affect the nerves that control 
muscle movement as well as those that transmit feelings 
of pain, temperature and touch, determining muscle weak-
ness and loss of sensation in the legs and/or arms. It is more 
common in adults and in males; however, people of all ag-
es can be affected. Around 3-5% of GBS patients die from 
complications like paralysis of the muscles of respiration, 
blood infection, lung embolus or cardiac arrest  [53, 54]. 
Etiology of GBS is still unknown, but infections from in-
fluenza, Cytomegalovirus, Zika Virus and C. jejuni can act 
as triggers for the onset of GBS [55-59].
What are the pathophysiological mechanisms under-
lying GBS?
Mechanisms are uncertain, but thought to be immune 
mediated and based on auto-immune reactions: immu-
nological similarity [60-62], production of anti-mye-
lin or anti-axonal glycoproteins antibodies induced by 
vaccine epitopes [63]. Alternatively it is also hypoth-
esized that vaccine components can interfere directly 
with peripheral nervous system structures  [64]. The 
time frame of onset considered for possible vaccine-
induced GBS is commonly up to 6 weeks after vacci-
nation, but some authors consider a longer time-frame 
(Fig. 1).
Which are the vaccines associated with GBS onset?
Several studies investigated the correlation between in-
fluenza vaccine and GBS occurrence, with mixed results 
(Tab. II).
Over the last years cumulative evidence on the increased 
incidence of GBS following H1N1 influenza vaccina-
tion in the 2009-2010 season was reported with a sig-
nificantly higher risk for non-adjuvanted vs adjuvanted 
vaccine [68, 70]. A European multinational case-control 
study on the same vaccine showed an increased risk of 
GBS post-vaccination, but after adjusting for upper res-
piratory tract infections, influenza-like illness or influ-
Fig. 2. Main factors affecting the need for cardiorespiratory monitoring after immunization.
Tab. II. GBS incidence in different influenza seasons (vaccinated vs 
non vaccinated subjects).
Influenza 
seasons
GBS incidence in vaccinated subjects 
(per million)
1976 (H1N1)
7.2 cases per million in the vaccinated 
group vs 0.79 cases per million in the non-
vaccinated group [64]
1991-1999
0.95 cases per million in the group 
vaccinated against influenza vs 0.22 cases 
per million in the group vaccinated against 
diphtheria-tetanus [65]
1990-2005
0.7 cases per million vaccinated 
subjects [66]
2000
0.86 cases per million vaccinated 
subjects [67]
2001
1.21 cases per million vaccinated 
subjects [68, 69]
2009 (H1N1)
1.6 excess cases per million vaccinated 
subjects [68, 69]
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enza vaccination, the association was no longer signifi-
cant [68, 71].
In this regard, epidemiological data from the available 
literature note that the relative risk (RR) of GBS follow-
ing vaccination is far lower than the one following an 
infectious disease (RR 1.41 vs 7.35 [68, 72-75]), espe-
cially in the case of influenza [76].
According to a recent simulation, assuming a typical 
influenza season and a typical vaccine effectiveness, in-
fluenza vaccination would reduce the individual risk of 
GBS [77, 78] (Tab. II).
In 2011, the Institute Of Medicine (IOM) could not con-
firm nor refute the causal relationship between GBS and 
anti measles, mumps, rubella, varicella, Hepatitis A Vi-
rus, Hepatitis B Virus, Human Papilloma Virus (HPV), 
influenza, diphtheria, tetanus and acellular pertussis vac-
cines because of inadequacy of available data. In 2004 
the IOM confirmed the causality between the 1976 in-
fluenza vaccine and GBS [8].
What are the risk factors for GBS and how do they 
affect immunization?
Concerning risk factors for post-vaccination GBS, the main 
one identified to date is the previous occurrence of GBS or 
the presence of GBS at the time of immunization [79, 80]. 
Therefore it is important to collect an adequate clinical his-
tory asking for previous occurrences of GBS.
What is the recommended action regarding immuni-
zation in case of previous episodes of GBS?
In individuals with a history of GBS, the risk of recurring 
GBS requiring hospitalization after vaccine administra-
tion is estimated at 1.18% in a study [81] and at 3.7% in 
another [80]. At the present time, the ability of influenza 
vaccination to cause GBS is not an established scientific 
finding. However, as a precautionary measure, it is ad-
vised not to administer vaccines to individuals who have 
experienced GBS in the previous 6 weeks unless they are 
at high risk for severe influenza complications; alterna-
tively, the possibility of antiviral chemoprophylaxis can 
be considered in these subjects  [79,  80]. For all other 
patients with a history of GBS outside of the 6 weeks 
interval, the decision to vaccinate should be based on 
risk-benefit balance assessment.
Vasculitides
How is a case of vasculitis defined and how frequent 
is it?
Vasculitides are a group of related disorders character-
ized by inflammation of blood vessels leading to tissue 
or end-organ injury with diverse and only partially un-
derstood etiology and with a wide spectrum of clinical 
manifestations and prognoses [82].
Vasculitis in children is rare. The annual incidence is 
estimated at about 53/100,000 subjects  [83]. The type 
of vasculitis depends primarily on age: in pediatric 
populations the most frequent vasculitides are Henoch-
Schönlein purpura (annual incidence: 10-20/100,000) 
and Kawasaki disease (annual incidence: 1-19/100,000; 
around 1/100 in Japanese newborns); in adults the most 
common is hypersensitivity vasculitis. Regarding the 
epidemiology of the different forms of vasculitis, varia-
tions are found depending on ethnic and geographic fac-
tors: Microscopic Polyangiitis occurs more frequently in 
Asia, Wegener’s granulomatosis in North America and 
northern Europe, Takayasu arteritis in Japan and Hor-
ton’s arteritis in Europe and North America. Almost all 
types of vasculitides have been tentatively implicated as 
AEs but only in a few there is evidence supporting this 
association [84].
What are the pathophysiological mechanisms under-
lying post-immunization vasculitides?
A causality relationship has not been established with 
certainty; the main hypothesis rests on the concept of 
molecular mimicry associated with circulating immune-
complex deposition [85].
Notwithstanding the uncertainty on the basic pathophys-
iological mechanism, in some cases of arthritis/arthral-
gia and vasculitides a mechanism can be found.
In 2011 the term Autoimmune/inflammatory Syndrome 
Induced by Adjuvants (ASIA)  [86] was coined to de-
scribe a group of autoimmune-derived clinical condi-
tions with similar symptoms, that occur after vaccina-
tion, supposedly induced by adjuvants [86-88]. Underly-
ing the onset of ASIA, an individual predisposition [89] 
and an environmental triggering factor (endogenous or 
exogenous) are necessary conditions. Molecular mim-
icry and overstimulation of the immune system are the 
pathophysiological mechanisms thought to be responsi-
ble for ASIA occurrence [90].
Which are the vaccines associated with vasculitides 
onset?
Over the last years several articles have been published 
on the correlation between vaccinations and vasculitides. 
The most frequently considered immunizations were in-
fluenza, Hepatitis B Virus, Bacillus Calmette-Guérin, 
Human Papilloma Virus, Meningococcal C conjugate 
and Hepatitis A Virus vaccines, while potentially cor-
related vasculitides were mostly cutaneous vasculitides, 
Henoch-Schönlein Purpura (HSP), Kawasaki Disease 
(KD). Fewer studies were performed on Systemic Lupus 
Eritematosus (SLE), ANCA-Associated Vasculitides 
(AAV), Giant Cell Arteritis (GCA) and Polyarteritis No-
dosa (PAN) [82].
At the present time the only associations that have not 
been rejected in evidence reviews are the following [84]:
• influenza vaccine and cutaneous vasculitides [91];
• influenza vaccine and GCA [92];
• Hepatitis B Virus (HBV) vaccine and Polyarteritis 
Nodosa (PAN) [85].
In particular, the association between vaccination and 
Kawasaki Disease, which is the second most frequent 
pediatric vasculitis [83] has been investigated in depth in 
the last few years. However, this possible association has 
been rejected based on assessments of Vaccine Adverse 
Events Reporting System (VAERS) data in 2009  [93] 
that demonstrated the absence of a temporal relationship 
between any vaccination and onset of KD symptoms. In 
spite of this evidence, the fear of an association of this 
disease with vaccination has remained high and pushed 
the Food and Drug Administration (FDA) to include it in 
the pentavalent anti Rotavirus vaccine adverse events re-
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porting, following the occurrence of 5 cases out of over 
36,000 vaccinated children during phase 3 research [94]. 
Another vaccination that has been associated with KD is 
Meningococcal B vaccine for which regulatory authori-
ties have requested ad-hoc post-marketing safety stud-
ies [95].
Finally, in 2015 a multicentric study was unable to dem-
onstrate an association between specific vaccinations 
and KD [96].
What are the risk factors for post-immunization vas-
culitides and how do they affect immunization?
Individual predisposition appears to be fundamental in 
the onset of these disorders [84].
A personal or family history of autoimmunity can rep-
resent a risk factor for certain vasculitides [97]. For pre-
cautionary reasons, it is advisable to follow subjects at 
risk for Giant Cell Arteritis (GCA) or Polymyalgia Rheu-
matica, depending on gender or age, for 2-6 months after 
influenza vaccination [92] (Fig. 1).
What is the recommended action regarding immuni-
zation in case of previous or current episodes of vas-
culitides?
There is mounting evidence that some infections can 
act as triggers for the onset of vasculitides, particularly 
Hepatitis B and C (HBV and HCV) viruses for PAN and 
respiratory tract infections for Henoch-Schönlein Pur-
pura (HSP). Infections have also been implicated in the 
relapse of some vasculitides, so that influenza and pneu-
mococcal vaccinations are recommended in affected 
subjects [98, 99], while in France a successful campaign 
of vaccination against HBV was followed by a decrease 
in the incidence of Polyarteritis Nodosa (PAN) [98].
Arthritis/Arthralgia (AA)
How is a case of AA defined and how frequent is it?
The term arthralgia is used in the medical literature to in-
dicate articular pain in general; in some cases arthralgia 
refers to a non-inflammatory condition of the joint, but 
this is not consistent in the literature. Among the causes 
of arthralgia are traumatic injury, degenerative processes 
of the joint, systemic inflammatory disorders, lupus, 
rheumatoid arthritis and vaccinations [100].
The word  arthritis is used by clinicians to specifically 
mean inflammation of the joints, while it is used in pub-
lic health to refer more generally to more than 100 rheu-
matic diseases and conditions that affect joints, the tis-
sues that surround the joint, and other connective tissue, 
and typically characterized by pain and stiffness in or 
around one or more joints. The pattern, severity, loca-
tion of symptoms, involvement of the immune system 
and other internal organs varies depending on the type 
of disease [101]. In 2012 in the US 52.5 million adults 
aged ≥ 18 years had self-reported or doctor-diagnosed 
arthritis, and 22.7 million reported arthritis-attributable 
activity limitation [102].
What are the pathophysiological mechanisms under-
lying post-immunization AA?
Several models have been proposed: a direct mechanism 
through polyclonal B cells activation and functional 
alteration of immune-regulatory cells and an indirect 
mechanism through the production of cytokines, mo-
lecular mimicry and immune-complex formation [103]. 
However, pathophysiological mechanisms post-immuni-
zation remain uncertain, as well as the period of onset 
(Fig. 1).
Possible mechanisms that have been postulated to cause 
in some cases the onset of post-immunization AA are 
the ones at the root of ASIA (See the section: “What 
are the pathophysiological mechanisms underlying post-
immunization vasculitides?”)
Which are the vaccines associated with AA onset?
Many vaccines, such as anti-Hepatitis A and B Viruses, 
measles, mumps, rubella, Varicella Zoster Virus and 
Human Papilloma Virus (HAV, HBV, MMR, VZV and 
HPV), have been implicated in the occurrence of AA as 
they can function as an exogenous trigger for the devel-
opment of autoimmune disorders [100, 105]. However, 
the role of vaccinations as possible causative agents of 
AA has not been established with sufficient evidence. 
In spite of this, many isolated cases or series of cases 
of arthritis following vaccination have been reported. 
These cases tend to be very infrequent and usually 
only short-term outcomes are described  [106]. In fact, 
the occurrence of post-vaccination arthritis/arthralgia 
(AA) is usually self-limiting and of moderate intensi-
ty [90, 104, 105].
What are the risk factors for post-immunization AA 
and how do they affect immunization?
In the case of rubella vaccination, possible risk factors 
are: advanced age, Human Leucocyte Antigens (HLA) 
dependent predisposition and female gender. Further 
studies however, found no evidence of increased risk for 
chronic arthropathy among women vaccinated against 
rubella.
However, in the absence of scientific evidence of the 
causal relationship between vaccination and AA and 
considering the overall risk-benefit balance, it can be 
stated that vaccination for the overwhelming majority of 
patients carries no risk of systemic autoimmune disease 
and should be administered according to current recom-
mendations [105, 107, 108].
What is the recommended action regarding immuni-
zation in case of previous episodes of AA?
Previous occurrence of episodes of AA or the presence of 
AA at the time of immunization is an important risk fac-
tor for the onset of post-immunization AA. However, for 
individuals suffering from AA, vaccination is still rec-
ommended because natural infection can cause a relapse 
of the AA symptoms. In order to give more information 
on timing and vaccination type to be administered, sev-
eral studies were conducted in recent years [109-115]:
• vaccination should be performed during the remis-
sion phase of the disorder and can be done in patients 
taking Disease Modifying Anti-Rheumatic Drugs 
(DMARDs) and anti-Tumor Necrosis Factor (TNF) 
drugs;
• vaccination should be performed before starting ther-
apy with anti-B cells drugs;
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• the administration of live attenuated vaccines, such 
as BCG, should be avoided, particularly in immuno-
suppressed individuals;
• some studies have shown efficacy and safety of non-
live vaccines in subjects whose condition is under 
pharmacologic control, even in those taking bio-
logic drugs; influenza and pneumococcal vaccines 
are strongly recommended in these patients and the 
choice of vaccine should be as personalized as pos-
sible since different Human Leucocyte Antigens 
(HLA) genetic polymorphisms cause inter-individual 
variation in terms of efficacy and toxicity.
It should be noted that, although vaccination is strongly 
recommended in these subjects, post-immunization re-
lapse or symptoms exacerbations can occur, possibly 
through a mechanism of polyclonal activation of B-cells 
or through cross-reactivity [90].
Immune Thrombocytopenic Purpura
How is a case of Immune Thrombocytopenic Purpura
(ITP) defined and how frequent is it?
The term refers to an autoimmune disorder of unknown 
etiology characterized by a platelet count < 100,000/ml 
and by the presence of small areas of hemorrhage (pur-
pura).
Data from surveillance system reports indicate that 
the frequency and severity of vaccine induced immune 
thrombocytopenic purpura (VI-ITP) is much lower than 
after natural infection from vaccine-preventable diseas-
es [116-119].
The incidence of VI-ITP is probably underestimated be-
cause mild to moderate and asymptomatic cases often do 
not come to the attention of physicians and are therefore 
not diagnosed and reported [120, 121].
What are the pathophysiological mechanisms under-
lying vaccine induced immune thrombocytopenic
purpura (VI-ITP)?
The occurrence of thrombocytopenia has been con-
vincingly related to the production of antibodies that 
cross-react with platelet antigens that can be detected in 
about 80% of cases [117-122]. In the case of thrombo-
cytopenia that occurs after anti measles-mumps-rubella 
(MMR) vaccination, the presence of anti-rubella and an-
ti-measles IgG antibodies that cross-react with platelet 
antigens has been consistently detected  [123-125]. For 
these reasons the pathophysiological mechanisms un-
derlying VI-ITP can be considered certain.
Which are the vaccines associated with VI-ITP on-
set?
Specific studies have been performed to assess VI-ITP as-
sociated with measles-mumps-rubella (MMR) and Hep-
atitis B Virus (HBV) vaccination, since the occurrence 
of immune thrombocytopenic purpura (ITP) is a possi-
ble complication of measles and HBV infection. Regard-
ing HBV vaccine, VI-ITP can occur after any dose of the 
vaccine and, in case of recurring episodes, the clinical 
picture tends to worsen, thus requiring specific treat-
ment [126]. VI-ITP that occurs after MMR vaccination 
has an onset within 6 weeks of vaccine administration 
and presents with a higher platelet count than ITP after 
natural infection [127] and with clinical manifestations 
such as petechiae of moderate severity [128], although 
rarely there have been reports of gastrointestinal (GI) 
and/or pulmonary hemorrhage  [129], hematuria  [130] 
and the need for splenectomy [131] (Fig. 1). The forms 
of VI-ITP that require hospitalization have a lower av-
erage duration of hospitalization than those caused by 
natural infection (3 vs 5 days) [133-135] and no deaths 
strictly correlated with VI-ITP after MMR vaccination 
have been reported, unlike in the case of natural infec-
tion  [117-121]. In the majority of cases (about 90%), 
VI-ITP is self-limiting within 6 months of diagnosis 
and only 10% turns into a chronic condition [127-128], 
whereas ITP after viral infection can become chronic 
in about 25% of cases on top of having a more severe 
clinical course [136]. A study performed on a cohort of 
1.8 million children and adolescents (age range: 7 weeks 
to 17 years of age) investigated the correlation between 
all vaccinations and the onset of ITP, considering a time 
frame from the date of immunization to 6 weeks after 
immunization. The results indicate an increase in risk 
after Hepatitis A Virus and Varicella Zoster Virus vac-
cinations performed between the 7th and 17th year of age 
and the 11th and 17th respectively [137] (Tab. III).
What are the risk factors for VI-ITP and how do they 
affect immunization?
The main risk factor for the onset of an episode of VI-
ITP is a previous episode of Immune Thrombocyto-
penic Purpura (ITP) or VI-ITP or the presence of ITP/
VI-ITP at the time of immunization  [117-121] (see 
below).
Tab. III. Increase of cases of Immune Thrombocytopenic Purpura (ITP) and their clinical course by selected vaccines.
Vaccine
Age range during which an increase in cases after 
vaccination occurred
Clinical course
MMR [137]
12th-19th month of age, 1 additional case every 40,000 
doses (p = 0.006); no changes with MMVR use
Usually moderate severity, in exceptional cases GI and/
or pulmonary hemorrhage. If hospitalization required, 
hospital stay shorter than in post-infection ITP
HAV [137] 7th-17th year of age (p = 0.001) *
VZV [137] 11th-17th year of age (p = 0.04) *
HBV [126] Inadequate evidence
Lack of guidelines; episodes appear to recur and become 
more severe after each vaccine administration
*Number of cases is insufficient to describe a typical clinical course.
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What is the recommended action regarding immuni-
zation in case of previous episodes of ITP or VI-ITP?
In subjects with a history of ITP or post-measles-mumps-
rubella (MMR) vaccine VI-ITP, with a normal platelet count 
at the time of immunization, MMR vaccine appears to be 
safe and well tolerated [117-121], although relapse of ITP 
can occasionally occur  [138,  139]. Recent studies claim 
that the first MMR dose does not normally trigger a relapse 
of ITP and that the booster dose is not followed by relapse 
within 6 weeks of administration [117-121]. However, the 
assessment of antibody titer against measles, mumps and 
rubella is recommended in patients with chronic ITP or with 
previous post-MMR VI-ITP to avoid further vaccine doses 
if the antibody titer is protective [119, 140, 141].
International guidelines on immune thrombocytopenia 
management recommend vaccination against S.  pneu-
moniae, H.  influenzae B and N.  meningitides before 
splenectomy [142].
Commentary and conclusions
As shown in this review, the issue of adverse events in 
the field of immunization is subject to a lot of uncer-
tainties, especially as regards rare and very rare ones; 
indeed, it is often not possible to conclude with suffi-
cient scientific rigor on causal relationships (or the lack 
thereof) between vaccines and adverse events [8]. This 
poses a significant problem in risk communication and 
risk management as health care workers need to provide 
fair and balanced information to patients while at the 
same time not discouraging immunization. Unfortunate-
ly, the asymmetry between the knowledge about benefits 
and the knowledge about risks is common throughout 
medicine.
It is important to keep in mind that the adverse events we 
have covered occur rarely or very rarely but that, at the 
same time, the benefits are not directly experienced by 
the individual who is vaccinated and that the tolerance 
for risks (real or perceived) in our societies is relatively 
low [143].
With many additional vaccines being developed and 
introduced in vaccination schedules, and with the re-
quirement to be immunized in order to be able to attend 
kindergarten and schools increasingly introduced or sug-
gested to fight vaccine hesitancy [144], the emphasis on 
vaccine safety and adverse event monitoring becomes 
increasingly important. It is also crucial to correctly 
identify, as far as possible, those individuals who are at 
higher risk for adverse events and require the adoption 
of additional precautions and follow-up after immuniza-
tion, and the few who need to be exempted for medical 
reasons. On the other hand, the current trend is against 
compulsory immunization (also on the basis of new evi-
dence showing poor results obtained where both com-
pulsory and voluntary vaccinations are simultaneously 
present in vaccine schedules) [145], while it is advised 
to counsel individuals in order to provide correct infor-
mation on benefits and risks, thus empowering them to 
make an informed choice.
For these reasons, as some important scientific bodies 
have suggested, it would be vital to obtain greater knowl-
edge on adverse events, possibly through the widespread 
use of electronic medical records that would enable a far 
higher sensitivity in epidemiologic assessments of rare/
very rare adverse events. Collecting evidence that fulfills 
causality criteria [146] will help both risk communica-
tion and decision making.
Furthermore, the additional knowledge accumulated 
through “mechanistic” biomedical research can help 
elucidate in greater detail the pathophysiological mecha-
nisms of vaccine induced harm and possibly help identi-
fy in advance the subjects at risk for harm, moving more 
and more towards tailored medicine.
Since there is no gold standard in risk communication 
in the field of vaccination, it is advisable to perform 
studies aimed at determining a more effective medi-
um of communication  [147]. It is important to bear 
in mind that vaccination risks should not be omitted 
both because it is unethical, and because considering 
a vaccine unsafe does not necessarily imply having 
doubts on its efficacy, therefore perceptions of vac-
cine importance may mitigate losses in vaccination 
uptake [148].
Trust in institutions such as Public Health and Gov-
ernment has effects on trust in immunization, and 
vice-versa  [147,  148]; it is necessary to develop a 
new strategy of risk communication that, rather than 
showing lists of adverse events, disease complications 
and their incidence, makes use of widely intelligible 
instruments and language, in order to clearly answer 
the questions of both Health Care Workers and Public 
Health services users.
Acknowledgments
Conflicts of Interest
EF received reimbursement for participating to meet-
ings and advisory boards by GSK, Pfizer, Sanofi Pasteur 
MSD, without any personal fee.
GLD’A, ET, EZ received reimbursement for participat-
ing to one scientific meeting and fee for giving scientific 
presentations by Sanofi Pasteur.
AC, GG, LZ declare absence of conflicts of interest.
References
[1] World Health Organization. Immunization, vaccines and bio-
logicals - Global Vaccine Action Plan. http://www.who.int/iris/
bitstream/10665/78141/1/9789241504980_eng.pdf?ua=1  [Last 
access: 01/09/2016].
[2] World Health Organization. Global Vaccine Action Plan 
2011-2020. http://www.who.int/immunization/global_vac-
cine_action_plan/GVAP_doc_2011_2020/en/ [Last access: 
01/09/2016].
[3] Dubé E, Vivion M, MacDonald NE. Vaccine hesitancy, vac-
cine refusal and the anti-vaccine movement: influence, impact 
and implications. Expert Rev Vaccines 2015;14:99-117. doi: 
10.1586/14760584.2015.964212.
[4] Cameron KA, Roloff ME, Friesema EM, Brown T, Jovanovic 
BD, Hauber S, Baker DW. Patient knowledge and recall of 
G.L. D’ALÒ ET AL.
E22
health information following exposure to “facts and myths“ 
message format variations. Patient Educ Couns 2013;92:381-7. 
doi: 10.1016/j.pec.2013.06.017.
[5] Centers for Disease Control and Prevention. Vaccine safety - 
Common vaccine safety concerns. Available at: http://www.
cdc.gov/vaccinesafety/Concerns/Index.html [Last access: 
30/08/2016.
[6] Directive 2001/83/EC of the European Parliament and of the 
Council of 6 November 2001 on the Community Code relating 
to medicinal products for human use.
[7] Causality assessment of adverse event following immunization 
(AEFI): user manual for the revised WHO classification. WHO/
HIS/EMP/QSS. MARCH 2013 glossary, p. VIII
[8] IOM (Institute of Medicine). Adverse effects of vaccines: Evi-
dence and causality. Washington, DC: The National Academies 
Press 2012.
[9] Piano Nazionale Prevenzione Vaccinale 2016-2018 (Draft), 
http://www.quotidianosanita.it/allegati/allegato1955037.pdf, 
last access: 30/08/2016.
[10] WHO-UMC Glossary of terms used in Pharmacovigilance, 
March 2011, http://who-umc.org/Graphics/24729.pdf
[11] Istituto Superiore di Sanità. Guida alle controindicazioni alle 
vaccinazioni. Available at: http://www.iss.it/binary/publ/
cont/09_13_web.pdf [Last access: 01/09/2016].
[12] International Conference on Harmonisation of technical re-
quirements for registration of pharmaceuticals for human use. 
ICH harmonised tripartite guideline - clinical safety data 
management: definitions and standards for expedited report-
ing E2A, 27 October 1994, https://www.ich.org/fileadmin/Pub-
lic_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/
E2A_Guideline.pdf
[13] Vermeer-de Bondt PE, Dzaferagić A, David S, van der Maas 
NA. Performance of the Brighton collaboration case defini-
tion for hypotonic-hyporesponsive episode (HHE) on reported 
collapse reactions following infant vaccinations in the Nether-
lands. Vaccine 2006;24:7066-70.
[14] Braun MM, Terracciano G, Salive ME, Blumberg DA, Vermeer-
de Bondt PE, Heijbel H, Evans G, Patriarca PA, Ellenberg SS. 
Report of a US public health service workshop on hypotonic-
hyporesponsive episode (HHE) after pertussis immunization. 
Pediatrics 1998;102:E52. doi: 10.1542/peds.102.5.e52.
[15] Gold MS. Hypotonic-hyporesponsive episodes following per-
tussis vaccination: a cause for concern? Drug Saf 2002;25:85-
90. doi: 10.2165/00002018-200225020-00003.
[16] Buettcher M, Heininger U, Braun M, Bonhoeffer J, Halperin S, 
Heijbel H, de Menezes Martins R, Vermeer-de Bondt P; Bright-
on Collaboration HHE Working Group. Hypotonic-hyporespon-
sive episode (HHE) as an adverse event following immunization 
in early childhood: case definition and guidelines for data col-
lection, analysis, and presentation. Vaccine 2007;25:5875-81. 
doi: 10.1016/j.vaccine.2007.04.061.
[17] Goodwin H, Nash M, Gold M, Heath TC, Burgess MA. Vacci-
nation of children following a previous hypotonic-hyporespon-
sive episode. J Paediatr Child Health 1999;35:549-52. PubMed 
PMID: 10634981.
[18] Monteiro SA, Takano OA, Waldman EA. Surveillance for ad-
verse events after DTwP/Hib vaccination in Brazil: sensitivity 
and factors associated with reporting. Vaccine 2010;28:3127-
33. doi: 10.1016/j.vaccine.2010.02.059.
[19] Kohl KS, Magnus M, Ball R, Halsey N, Shadomy S, Farley 
TA. Applicability, reliability, sensitivity, and specificity of six 
Brighton Collaboration standardized case definitions for ad-
verse events following immunization. Vaccine 2008;26:6349-60. 
doi: 10.1016/j.vaccine.2008.09.002.
[20] Bonhoeffer J, Gold MS, Heijbel H, Vermeer P, Blumberg D, Braun 
M, de Souza-Brito G, Davis RL, Halperin S, Heininger U, Khuri-
Bulos N, Menkes J, Nokleby H; Brighton Collaboration HHE 
Working Group. Hypotonic-Hyporesponsive Episode (HHE) as 
an adverse event following immunization: case definition and 
guidelines for data collection, analysis, and presentation. Vaccine 
2004;22:563-8. doi: 10.1016/j.vaccine.2003.09.009.
[21] Fotis L, Vazeou A, Xatzipsalti M, Stamoyannou L. Hypotonic 
hyporesponsive episode and the 13-valent pneumococcal vac-
cine. Turk J Pediatr 2014;56:427-9.
[22] Czajka H, Wysocki J. Hypotonic-hyporesponsive episode 
(HHE) following vaccination with a combined vaccine against 
diphtheria, tetanus and pertussis (whole cell vaccine -DTPv). 
Neurol Neurochir Pol 2004;38(1 Suppl 1):S17-24.
[23] National Clinical Guideline Centre (UK). Multiple Sclerosis: Man-
agement of Multiple Sclerosis in Primary and Secondary Care. Lon-
don: National Institute for Health and Care Excellence (UK) 2014.
[24] WHO. Atlas: Multiple Sclerosis Resources in the 
World 2008. Available at http://apps.who.int/iris/bitstre
am/10665/43968/1/9789241563758_eng.pdf
[25] Ascherio A, Zhang SM, Hernán MA, Olek MJ, Coplan PM, 
Brodovicz K, Walker AM. Hepatitis B vaccination and the 
risk of multiple sclerosis. N Engl J Med 2001;344:327-32. doi: 
10.1056/NEJM200102013440502.
[26] Touzé E, Gout O, Verdier-Taillefer MH, Lyon-Caen O, Alpéro-
vitch A. [The first episode of central nervous system demyelini-
zation and hepatitis B virus vaccination]. Rev Neurol (Paris) 
2000;156:242-6.
[27] Langer-Gould A, Qian L, Tartof SY, Brara SM, Jacobsen SJ, 
Beaber BE, Sy LS, Chao C, Hechter R, Tseng HF. Vaccines and 
the risk of multiple sclerosis and other central nervous system 
demyelinating diseases. JAMA Neurol 2014;71:1506-13. doi: 
10.1001/jamaneurol.2014.2633.
[28] Mikaeloff Y, Caridade G, Suissa S, Tardieu M. Hepatitis B 
vaccine and the risk of CNS inflammatory demyelination 
in childhood. Neurology 2009;72:873-80. doi: 10.1212/01.
wnl.0000335762.42177.07.
[29] Thome J. Immunizations in Adults Taking Disease-modifying 
Antirheumatic Drugs. US Pharmacist 2013;38:38-43.
[30] Williamson EM, Chahin S, Berger JR. Vaccines in Multiple 
Sclerosis. Curr Neurol Neurosci Rep 2016;16:36. doi: 10.1007/
s11910-016-0637-6.
[31] Eichenwald EC and AAP committee on fetus and newborn. Ap-
nea of prematurity. Pediatrics 2016;137:e20153757
[32] Mathew OP. Apnea of prematurity: pathogenesis and man-
agement strategies. J Perinatol 2011;31:302-10. doi: 10.1038/
jp.2010.126.
[33] Slack MH, Schapira D. Severe apnoeas following immunisa-
tion in premature infants. Arch Dis Child Fetal Neonatal Ed 
1999;81:F67-8. doi: 10.1136/fn.81.1.F67.
[34] Sánchez PJ, Laptook AR, Fisher L, Sumner J, Risser RC, Perl-
man JM. Apnea after immunization of preterm infants. J Pediatr 
1997;130:746-51. doi: 10.1016/S0022-347680017-0.
[35] Botham SJ, Isaacs D. Incidence of apnoea and bradycardia 
in preterm infants following triple antigen immunization. J 
Paediatr Child Health 1994;30:533-5. doi: 10.1111/j.1440-
1754.1994.tb00728.x.
[36] Botham SJ, Isaacs D, Henderson-Smart DJ. Incidence of ap-
noea and bradycardia in preterm infants following DTPw and 
Hib immunization: a prospective study. J Paediatr Child Health 
1997;33:418-21. 
[37] Lee J, Robinson JL, Spady DW. Frequency of apnea, brady-
cardia, and desaturations following first diphtheria-tetanus-
pertussis-inactivated polio-Haemophilus influenzae type B 
immunization in hospitalized preterm infants. BMC Pediatr 
2006;6:20. doi: 10.1186/1471-2431-6-20.
[38] Pourcyrous M, Korones SB, Arheart KL, Bada HS. Primary 
immunization of premature infants with gestational age < 35 
weeks: cardiorespiratory complications and C-reactive 
protein responses associated with administration of single 
and multiple separate vaccines simultaneously. J Pediatr 
2007;151:167-72.
FREQUENTLY ASKED QUESTIONS ON SEVEN RARE ADVERSE EVENTS  
FOLLOWING IMMUNIZATION
E23
[39] Pourcyrous M, Korones SB, Crouse D, Bada HS. Interleukin-6, 
C-reactive protein, and abnormal cardiorespiratory responses 
to immunization in premature infants. Pediatrics 1998;101:E3. 
doi: 10.1542/peds.101.3.e3.
[40] Cohen G, Lagercrantz H, Katz-Salamon M. Abnormal cir-
culatory stress responses of preterm graduates. Pediatr Res 
2007;61:329-34. doi: 10.1203/pdr.0b013e318030d0ef.
[41] Flatz-Jequier A, Posfay-Barbe KM, Pfister RE, Siegrist CA. 
Recurrence of cardiorespiratory events following repeat 
DTaP-based combined immunization in very low birth weight 
premature infants. J Pediatr 2008;153:429-31. doi: 10.1016/j.
jpeds.2008.03.043.
[42] Cooper PA, Madhi SA, Huebner RE, Mbelle N, Karim SS, 
Kleinschmidt I, Forrest BD, Klugman KP. Apnea and its pos-
sible relationship to immunization in ex-premature infants. Vac-
cine 2008;26:3410-3. doi: 10.1016/j.vaccine.2008.04.037.
[43] Sen S, Cloete Y, Hassan K, Buss P. Adverse events following 
vaccination in premature infants. Acta Paediatr 2001;90:916-
20. doi: 10.1111/j.1651-2227.2001.tb02457.x.
[44] Pfister RE, Aeschbach V, Niksic-Stuber V, Martin BC, Siegrist 
CA. Safety of DTaP-based combined immunization in very-low-
birth-weight premature infants: frequent but mostly benign car-
diorespiratory events. J Pediatr 2004;145:58-66. doi: 10.1016/j.
jpeds.2004.04.006.
[45] Slack MH, Schapira C, Thwaites RJ, Andrews N, Schapira D. 
Acellular pertussis and meningococcal C vaccines: cardio-res-
piratory events in preterm infants. Eur J Pediatr 2003;162:436-7.
[46] Faldella G, Galletti S, Corvaglia L, Ancora G, Alessandroni R. 
Safety of DTaP-IPV-HIb-HBV hexavalent vaccine in very pre-
mature infants. Vaccine 2007;25:1036-42. doi: 10.1016/j.vac-
cine.2006.09.065.
[47] Klein NP, Massolo ML, Greene J, Dekker CL, Black S, Escobar 
GJ;Vaccine Safety Datalink. Risk factors for developing apnea 
after immunization in the neonatal intensive care unit. Pediat-
rics 2008;121:463-9. doi: 10.1542/peds.2007-1462.
[48] Hacking DF, Davis PG, Wong E, Wheeler K, McVernon J. 
Frequency of respiratory deterioration after immunisation in 
preterm infants. J Paediatr Child Health 2010;46:742-8. doi: 
10.1111/j.1440-1754.2010.01832.x.
[49] Gaudelus J, Lefèvre-Akriche S, Roumegoux C, Bolie S, Belas-
co C, Letamendia-Richard E, Lachassinne E. [Immunization of 
the preterm infant]. Arch Pediatr 2007;14(Suppl 1):S24-30.
[50] Esposito S, Serra D, Gualtieri L, Cesati L, Principi N. Vac-
cines and preterm neonates: why, when, and with what. Early 
Hum Dev 2009;85(10  Suppl):S43-5. doi: 10.1016/j.earlhum-
dev.2009.08.011.
[51] Saari TN; American Academy of Pediatrics Committee on 
Infectious Diseases. Immunization of preterm and low birth 
weight infants. American Academy of Pediatrics Committee 
on Infectious Diseases. Pediatrics 2003;112(1 Pt 1):193-8. doi: 
10.1542/peds.112.1.193.
[52] Clifford V, Crawford NW, Royle J, Lazzaro T, Danchin M, Per-
rett KP, Lee KJ, Buttery JP. Recurrent apnoea post immunisa-
tion: Informing re-immunisation policy. Vaccine 2011;29:5681-
7. doi: 10.1016/j.vaccine.2011.06.005.
[53] World Health Organization. Guillain–Barré syndrome – fact 
sheet – updated October 2016. Available at: http://www.who.
int/mediacentre/factsheets/guillain-barre-syndrome/en/ [Last 
access: 14/10/2016].
[54] Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 
2012;366:2294-304. doi: 10.1056/NEJMra1114525.
[55] D’Alò GL, Ciabattini M, Zaratti L, Franco E. [Zika virus: a 
public health overview on epidemiology, clinical practice and 
prevention]. Ig Sanita Pubbl 2016;72:161-80.
[56] Israeli E, Agmon-Levin N, Blank M, Chapman J, Shoenfeld Y. 
Guillain-Barré syndrome--a classical autoimmune disease trig-
gered by infection or vaccination. Clin Rev Allergy Immunol 
2012;42:121-30. doi: 10.1007/s12016-010-8213-3.
[57] Louwen R, Horst-Kreft D, de Boer AG, van der Graaf L, de 
Knegt G, Hamersma M, Heikema AP, Timms AR, Jacobs BC, 
Wagenaar JA, Endtz HP, van der Oost J, Wells JM, Nieuwenhuis 
EE, van Vliet AH, Willemsen PT, van Baarlen P, van Belkum A. A 
novel link between Campylobacter jejuni bacteriophage defence, 
virulence and Guillain-Barré syndrome. Eur J Clin Microbiol In-
fect Dis 2013;32:207-26. doi: 10.1007/s10096-012-1733-4.
[58] Orlikowski D, Porcher R, Sivadon-Tardy V, Quincampoix 
JC, Raphaël JC, Durand MC, Sharshar T, Roussi J, Caudie C, 
Annane D, Rozenberg F, Leruez-Ville M, Gaillard JL, Gault 
E. Guillain-Barré syndrome following primary cytomegalo-
virus infection: a prospective cohort study. Clin Infect Dis 
2011;52:837-44. doi: 10.1093/cid/cir074.
[59] Sivadon-Tardy V, Orlikowski D, Porcher R, Sharshar T, Du-
rand MC, Enouf V, Rozenberg F, Caudie C, Annane D, van der 
Werf S, Lebon P, Raphaël JC, Gaillard JL, Gault E. Guillain-
Barré syndrome and influenza virus infection. Clin Infect Dis 
2009;48:48-56. doi: 10.1086/594124.
[60] Poser CM, Behan PO. Late onset of Guillain-Barré syndrome. J 
Neuroimmunol 1982;3:27-41.
[61] Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and au-
toimmunity. Nat Rev Rheumatol 2009;5:648-52. doi: 10.1038/
nrrheum.2009.196.
[62] Tomljenovic L, Shoenfeld Y. Association between vaccination 
and Guillain-Barré syndrome. Lancet Infect Dis 2013;13:730-1. 
doi: 10.1016/S1473-309970142-7.
[63] Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and 
Guillain-Barré syndrome. Drug Saf 2009;32:309-23. doi: 
10.2165/00002018-200932040-00005.
[64] Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside 
RA, Ziegler DW, Retailliau HF, Eddins DL, Bryan JA. Guillain-
Barré syndrome following vaccination in the National Influenza 
Immunization Program, United States, 1976-1977. Am J Epide-
miol 1979;110:105-23.
[65] Geier MR, Geier DA, Zahalsky AC. Influenza vaccination and 
Guillain Barre syndrome. Clin Immunol 2003;107:116-21.
[66] Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, 
Haber P. Safety of trivalent inactivated influenza vaccines in 
adults: background for pandemic influenza vaccine safety 
monitoring. Vaccine 200926;27:2114-20. doi: 10.1016/j.vac-
cine.2009.01.125.
[67] Burwen DR, Ball R, Bryan WW, Izurieta HS, La Voie L, Gibbs 
NA, Kliman R, Braun MM. Evaluation of Guillain-Barré 
Syndrome among recipients of influenza vaccine in 2000 and 
2001. Am J Prev Med 2010;39:296-304. doi: 10.1016/j.ame-
pre.2010.05.022.
[68] Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, 
Burwen DR, Cunningham F, Garman P, Greene SK, Lee GM, 
Vellozzi C, Yih WK, Gellin B, Lurie N; H1N1 GBS Meta-
Analysis Working Group. Association between Guillain-Barré 
syndrome and influenza A (H1N1) 2009 monovalent inactivated 
vaccines in the USA: a meta-analysis. Lancet 2013;381:1461-8. 
doi: 10.1016/S0140-673662189-8.
[69] Salmon DA, Halsey NA. Editorial commentary: Guillain-Barré 
syndrome and vaccinations. Clin Infect Dis 2013;57:205-7. doi: 
10.1093/cid/cit218.
[70] Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, 
Sturkenboom M, Zuber P, Hua W, Bonhoeffer J, Buttery J, 
Crawford N, Deceuninck G, de Vries C, De Wals P, Gut-
ierrez-Gimeno MV, Heijbel H, Hughes H, Hur K, Hviid 
A, Kelman J, Kilpi T, Chuang SK, Macartney K, Rett M, 
Lopez-Callada VR, Salmon D, Gimenez-Sanchez F, Sanz N, 
Silverman B, Storsaeter J, Thirugnanam U, van der Maas N, 
Yih K, Zhang T, Izurieta H; Global H1N1 GBS Consortium. 
International collaboration to assess the risk of Guillain 
Barré Syndrome following Influenza A (H1N1) 2009 mono-
valent vaccines. Vaccine 2013;31:4448-58. doi: 10.1016/j.
vaccine.2013.06.032.
[71] Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, 
G.L. D’ALÒ ET AL.
E24
Sturkenboom M; VAESCO-GBS Case-Control Study Group. 
Guillain-Barre syndrome and adjuvanted pandemic influenza A 
(H1N1) 2009 vaccine: multinational case-control study in Eu-
rope. BMJ 2011;343:d3908. doi: 10.1136/bmj.d3908.
[72] Stowe J, Andrews N, Wise L, Miller E. Investigation of the 
temporal association of Guillain-Barre syndrome with influ-
enza vaccine and influenzalike illness using the United King-
dom General Practice Research Database. Am J Epidemiol 
2009;169:382-8. doi: 10.1093/aje/kwn310+.
[73] Poland GA, Poland CM, Howe CL. Influenza vaccine and 
Guillain-Barré syndrome: making informed decisions. Lancet 
2013;381:1437-9. doi: 10.1016/S0140-673660182-8.
[74] Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influ-
enza, and influenza vaccination: the epidemiologic evidence. 
Clin Infect Dis 2014;58:1149-55. doi: 10.1093/cid/ciu005.
[75] Vellozzi C, Iqbal S, Stewart B, Tokars J, DeStefano F. Cumu-
lative risk of Guillain-Barré syndrome among vaccinated and 
unvaccinated populations during the 2009 H1N1 influenza pan-
demic. Am J Public Health 2014;104:696-701. doi: 10.2105/
AJPH.2013.301651.
[76] Martín Arias LH, Sanz R, Sáinz M, Treceño C, Carvajal A. Guil-
lain-Barré syndrome and influenza vaccines: A meta-analysis. 
Vaccine 2015;33:3773-8. doi: 10.1016/j.vaccine.2015.05.013.
[77] Hawken S, Kwong JC, Deeks SL, Crowcroft NS, McGeer AJ, 
Ducharme R, Campitelli MA, Coyle D, Wilson K. Simulation 
study of the effect of influenza and influenza vaccination on 
risk of acquiring Guillain-Barré syndrome. Emerg Infect Dis 
2015;21:224-31. doi: 10.3201/eid2102.131879.
[78] Andrews N, Stowe J, Al-Shahi Salman R, Miller E. Guillain-
Barré syndrome and H1N1 (2009) pandemic influenza vacci-
nation using an AS03 adjuvanted vaccine in the United King-
dom: self-controlled case series. Vaccine 2011;29:7878-82. doi: 
10.1016/j.vaccine.2011.08.069.
[79] Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton 
JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ; 
Centers for Disease Control and Prevention (CDC). Preven-
tion and control of influenza with vaccines: recommendations 
of the Advisory Committee on Immunization Practices (ACIP), 
2010. MMWR Recomm Rep 2010;59(RR-8):1-62. Erratum in: 
MMWR Recomm Rep 2010;59:993. MMWR Recomm Rep 
2010;59:1147.
[80] Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van 
Doorn PA. Recurrences, vaccinations and long-term symptoms 
in GBS and CIDP. J Peripher Nerv Syst 2009;14:310-5. doi: 
10.1111/j.1529-8027.2009.00243.x.
[81] Pritchard J, Mukherjee R, Hughes RA. Risk of relapse of 
Guillain-Barré syndrome or chronic inflammatory demyeli-
nating polyradiculoneuropathy following immunisation. J 
Neurol Neurosurg Psychiatry 2002;73:348-9. PubMed PMID: 
12185184;PubMed Central PMCID: PMC1738021.
[82] Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic 
vasculitis--is it time to reclassify? Rheumatology (Oxford) 
2011;50:643-5. doi: 10.1093/rheumatology/keq229.
[83] Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood 
TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, 
and rare vasculitides in children of different ethnic origins. Lan-
cet 2002;360:1197-202. doi: 10.1016/S0140-673611279-7.
[84] Bonetto C, Trotta F, Felicetti P, Alarcón GS, Santuccio C, Bach-
tiar NS, Brauchli Pernus Y, Chandler R, Girolomoni G, Hadden 
RD, Kucuku M, Ozen S, Pahud B, Top K, Varricchio F, Wise 
RP, Zanoni G, Živković S, Bonhoeffer J; Brighton Collabora-
tion Vasculitis Working Group. Vasculitis as an adverse event 
following immunization - Systematic literature review. Vaccine 
2016;34:6641-51. doi: 10.1016/j.vaccine.2015.09.026
[85] de Carvalho JF, Pereira RM, Shoenfeld Y. Systemic polyarteri-
tis nodosa following hepatitis B vaccination. Eur J Intern Med 
2008;19:575-8. doi: 10.1016/j.ejim.2007.06.035.
[86] Shoenfeld Y, Agmon-Levin N. ‘ASIA’ - autoimmune/inflamma-
tory syndrome induced by adjuvants. J Autoimmun 2011;36:4-
8. doi: 10.1016/j.jaut.2010.07.003.
[87] Agmon-Levin N, Hughes GR, Shoenfeld Y. The spec-
trum of ASIA: ‘Autoimmune (Auto-inflammatory) Syn-
drome induced by Adjuvants’. Lupus 2012;21:118-20. doi: 
10.1177/0961203311429316. 
[88] Zafrir Y, Agmon-Levin N, Paz Z, Shilton T, Shoenfeld Y. Auto-
immunity following hepatitis B vaccine as part of the spectrum 
of ‘Autoimmune (Auto-inflammatory) Syndrome induced by Ad-
juvants’ (ASIA): analysis of 93 cases. Lupus 2012;21:146-52. 
doi: 10.1177/0961203311429318.
[89] Toubi E. ASIA-autoimmune syndromes induced by adjuvants: 
rare, but worth considering. Isr Med Assoc J 2012;14:121-4.
[90] Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-
Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome 
induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, 
clinical and diagnostic aspects. J Autoimmun 2013;47:1-16. 
doi: 10.1016/j.jaut.2013.10.004.
[91] Hehn J, Hartmann K, Bröcker EB, Goebeler M. [Influenza vac-
cination and skin disease--coincidence or causal association?]. 
J Dtsch Dermatol Ges 2003;1:99-104.
[92] Soriano A, Verrecchia E, Marinaro A, Giovinale M, Fon-
nesu C, Landolfi R, Manna R. Giant cell arteritis and poly-
myalgia rheumatica after influenza vaccination: report of 10 
cases and review of the literature. Lupus 2012;21:153-7. doi: 
10.1177/0961203311430222.
[93] Hua W, Izurieta HS, Slade B, Belay ED, Haber P, Tiernan R, 
Woo EJ, Iskander J, Braun MM, Ball R. Kawasaki disease af-
ter vaccination: reports to the vaccine adverse event reporting 
system 1990-2007. Pediatr Infect Dis J 2009;28:943-7. doi: 
10.1097/INF.0b013e3181a66471.
[94] U.S. Food and Drug Administration. Highlights of Pre-
scribing Information - RotaTeq (Rotavirus Vaccine, Live, 
Oral, Pentavalent) Oral Solution. Available at: https://
www.fda.gov/downloads/BiologicsBloodVaccines/Vac-
cines/ApprovedProducts/UCM137249.pdf. [Last access: 
01/09/2016].
[95] EMA Bexsero public assessment report http://www.ema.eu-
ropa.eu/docs/en_GB/document_library/EPAR_-_Public_as-
sessment_report/human/002333/WC5001378
[96] Abrams JY, Weintraub ES, Baggs JM, McCarthy NL, Schonberg-
er LB, Lee GM, Klein NP, Belongia EA, Jackson ML, Naleway 
AL, Nordin JD, Hambidge SJ, Belay ED. Childhood vaccines and 
Kawasaki disease, Vaccine Safety Datalink, 1996-2006. Vaccine 
2015;33:382-7. doi: 10.1016/j.vaccine.2014.10.044.
[97] Gatto M, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal 
R, Kivity S, Doria A, Shoenfeld Y. Human papillomavirus 
vaccine and systemic lupus erythematosus. Clin Rheumatol 
2013;32:1301-7. doi: 10.1007/s10067-013-2266-7.
[98] Guillevin L. Infections in vasculitis. Best Pract Res Clin Rheu-
matol 2013;27:19-31. doi: 10.1016/j.berh.2013.01.004.
[99] Piram M, Mahr A. Epidemiology of immunoglobulin A 
vasculitis (Henoch-Schönlein): current state of knowl-
edge. Curr Opin Rheumatol 2013;25:171-8. doi: 10.1097/
BOR.0b013e32835d8e2a.
[100] Rippe JM. Encyclopedia of Lifestyle. Medicine and Health 
2011, p. 81.
[101] http://www.cdc.gov/arthritis/basics/general.htm, last access 
29/07/2016
[102] Centers for Disease Control and Prevention (CDC). Prevalence 
of doctor-diagnosed arthritis and arthritis-attributable activity 
limitation – United States, 2010-2012. MMWR Morb Mortal 
Wkly Rep 2013;62:869-73
[103] Gualberto FA, Curti SP, de Oliveira MI, Moraes-Vasconcelos D, 
Figueiredo CA. Intermittent rash, lymph node swelling, arthral-
gia and vaccinal viral detection after rubella immunization. J 
Clin Virol 2013;56:93-5. doi: 10.1016/j.jcv.2012.07.017.
FREQUENTLY ASKED QUESTIONS ON SEVEN RARE ADVERSE EVENTS  
FOLLOWING IMMUNIZATION
E25
[104] Sukumaran L, McNeil MM, Moro PL, Lewis PW, Winiecki SK, 
Shimabukuro TT. Adverse Events Following Measles, Mumps, 
and Rubella Vaccine in Adults Reported to the Vaccine Adverse 
Event Reporting System (VAERS), 2003-2013. Clin Infect Dis 
2015;60:e58-65. doi: 10.1093/cid/civ061.
[105] Schattner A. Consequence or coincidence? The occurrence, 
pathogenesis and significance of autoimmune manifestations 
after viral vaccines. Vaccine 2005;23:3876-86.
[106] Toussirot É, Bereau M. Vaccination and Induction of Autoim-
mune Diseases. Inflamm Allergy Drug Targets 2015;14:94-8.
[107] Slater PE, Ben-Zvi T, Fogel A, Ehrenfeld M, Ever-Hadani S. Ab-
sence of an association between rubella vaccination and arthritis 
in underimmune postpartum women. Vaccine 1995;13:1529-32.
[108] Ray P, Black S, Shinefield H, Dillon A, Schwalbe J, Holmes S, 
Hadler S, Chen R, Cochi S, Wassilak S. Risk of chronic arthrop-
athy among women after rubella vaccination. Vaccine Safety 
Datalink Team. JAMA 1997;278:551-6.
[109] van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran 
MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, 
Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, 
Valesini G, Wulffraat NM, Bijl M. EULAR recommendations 
for vaccination in adult patients with autoimmune inflamma-
tory rheumatic diseases. Ann Rheum Dis 2011;70:414-22. doi: 
10.1136/ard.2010.137216.
[110] Bijl M, Agmon-Levin N, Dayer JM, Israeli E, Gatto M, Shoenfeld 
Y. Vaccination of patients with auto-immune inflammatory rheu-
matic diseases requires careful benefit-risk assessment. Autoim-
mun Rev 2012;11:572-6. doi: 10.1016/j.autrev.2011.10.015.
[111] Perricone C, Agmon-Levin N, Valesini G, Shoenfeld Y. Vac-
cination in patients with chronic or autoimmune rheumatic 
diseases: the ego, the id and the superego. Joint Bone Spine 
2012;79:1-3. doi: 10.1016/j.jbspin.2011.10.006.
[112] Thomas C, Moridani M. Interindividual variations in the ef-
ficacy and toxicity of vaccines. Toxicology 2010;278:204-10. 
doi: 10.1016/j.tox.2009.10.008.
[113] Nerome Y, Akaike H, Nonaka Y, Takezaki T, Kubota T, Yama-
to T, Yamasaki Y, Imanaka H, Kawano Y, Takei S. The safety 
and effectiveness of HBV vaccination in patients with juvenile 
idiopathic arthritis controlled by treatment. Mod Rheumatol 
2016;26:368-71. doi: 10.3109/14397595.2015.1085608.
[114] Rákóczi É, Perge B, Végh E, Csomor P, Pusztai A, Szamosi 
S, Bodnár N, Szántó S, Szücs G, Szekanecz Z. Evaluation 
of the immunogenicity of the 13-valent conjugated pneumo-
coccal vaccine in rheumatoid arthritis patients treated with 
etanercept. Joint Bone Spine 2016;83:675-9. doi: 10.1016/j.
jbspin.2015.10.017.
[115] Alten R, Bingham CO 3rd, Cohen SB, Curtis JR, Kelly S, Wong 
D, Genovese MC. Antibody response to pneumococcal and in-
fluenza vaccination in patients with rheumatoid arthritis receiv-
ing abatacept. BMC Musculoskelet Disord 2016;17:231. doi: 
10.1186/s12891-016-1082-z.
[116] Grimaldi-Bensouda L, Michel M, Aubrun E, Leighton P, Vial-
lard JF, Adoue D, Magy-Bertrand N, Tisserand G, Khellaf M, 
Durand JM, Quittet P, Fain O, Bonnotte B, Morin AS, Limal N, 
Costedoat-Chalumeau N, Morel N, Pan-Petesch B, Decaux O, 
Mahevas M, Ruel M, Sacre K, Lefrere F, Abenhaim L, Godeau 
B; PGRx Immune Thrombocytopenia Study Group. A case-
control study to assess the risk of immune thrombocytopenia as-
sociated with vaccines. Blood 2012;120:4938-44. doi: 10.1182/
blood-2012-05-431098.
[117] Cecinati V, Principi N, Brescia L, Giordano P, Esposito S. Vac-
cine administration and the development of immune throm-
bocytopenic purpura in children. Hum Vaccin Immunother 
2013;9:1158-62. doi: 10.4161/hv.23601.
[118] Woo EJ, Wise RP, Menschik D, Shadomy SV, Iskander J, Beeler 
J, Varricchio F, Ball R. Thrombocytopenia after vaccination: 
case reports to the US Vaccine Adverse Event Reporting Sys-
tem, 1990-2008. Vaccine 2011;29:1319-23. doi: 10.1016/j.vac-
cine.2010.11.051.
[119] Sauvé LJ, Scheifele D. Do childhood vaccines cause thrombo-
cytopenia? Paediatr Child Health 2009;14:31-2.
[120] Rejjal AL, Britten G, Nazer H. Thrombocytopenic purpura fol-
lowing measles-mumps-rubella vaccination. Ann Trop Paediatr 
1993;13:103-4.
[121] Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic 
purpura after measles-mumps-rubella vaccination: a system-
atic review of the literature and guidance for management. J 
Pediatr 2010;156:623-8. doi: 10.1016/j.jpeds.2009.10.015.
[122] Fujita H. [Idiopathic thrombocytopenic purpura following viral 
infection]. Nihon Rinsho 2003;61:650-4.
[123] Johnsen J. Pathogenesis in immune thrombocytopenia: 
new insights. Hematology Am Soc Hematol Educ Program 
2012;2012:306-12. doi: 10.1182/asheducation-2012.1.306.
[124] Okazaki N, Takeguchi M, Sonoda K, Handa Y, Kakiuchi T, Mi-
yahara H, Akiyoshi K, Korematsu S, Suenobu S, Izumi T. De-
tection of platelet-binding anti-measles and anti-rubella virus 
IgG antibodies in infants with vaccine-induced thrombocyto-
penic purpura. Vaccine 2011;29:4878-80. doi: 10.1016/j.vac-
cine.2011.04.036.
[125] Chen RT, Pless R, Destefano F. Epidemiology of autoimmune 
reactions induced by vaccination. J Autoimmun 2001;16:309-
18. doi: 10.1006/jaut.2000.0491.
[126] Meyboom RH, Fucik H, Edwards IR. Thrombocytopenia re-
ported in association with hepatitis B and A vaccines. Lancet 
1995;345:1638. doi: 10.1016/S0140-673690143-4.
[127] France EK, Glanz J, Xu S, Hambidge S, Yamasaki K, Black 
SB, Marcy M, Mullooly JP, Jackson LA, Nordin J, Belongia 
EA, Hohman K, Chen RT, Davis R; Vaccine Safety Data-
link Team. Risk of immune thrombocytopenic purpura after 
measles-mumps-rubella immunization in children. Pediatrics 
2008;121:e687-92. doi: 10.1542/peds.2007-1578.
[128] Black C, Kaye JA, Jick H. MMR vaccine and idiopathic throm-
bocytopaenic purpura. Br J Clin Pharmacol 2003 Jan;55:107-
11. doi: 10.1046/j.1365-2125.2003.01790.x.
[129] Nieminen U, Peltola H, Syrjälä MT, Mäkipernaa A, Kekomäki 
R. Acute thrombocytopenic purpura following measles, mumps 
and rubella vaccination. A report on 23 patients. Acta Paediatr 
1993;82:267-70. doi: 10.1111/j.1651-2227.1993.tb12657.x.
[130] Jonville-Béra AP, Autret E, Galy-Eyraud C, Hessel L. Throm-
bocytopenic purpura after measles, mumps and rubella vac-
cination: a retrospective survey by the French regional phar-
macovigilance centres and pasteur-mérieux sérums et vaccins. 
Pediatr Infect Dis J 1996;15:44-8. doi: 10.1097/00006454-
199601000-00010.
[131] Ozsoylu S, Kanra G, Savaş G. Thrombocytopenic purpura re-
lated to rubella infection. Pediatrics 1978;62:567-9.
[132] Chang S, O’Connor PM, Slade BA, Woo EJ. U.S. Postlicen-
sure safety surveillance for adolescent and adult tetanus, diph-
theria and acellular pertussis vaccines: 2005-2007. Vaccine 
2013;31:1447-52. doi: 10.1016/j.vaccine.2012.10.097.
[133] Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Tay-
lor B. Idiopathic thrombocytopenic purpura and MMR vaccine. 
Arch Dis Child 2001;84:227-9.
[134] Sladden RA. Thrombocytopenic purpura and rubella. Br Med J 
1963;2:1587-8.
[135] Morse EE, Zinkham WH, Jackson DP. Thrombocytopenic pur-
pura following rubella infection in children and adults. Arch 
Intern Med 1966;117:573-9.
[136] Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Ar-
nold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau 
B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach 
P, Blanchette V, Kühne T, Ruggeri M, George JN. Standardiza-
tion of terminology, definitions and outcome criteria in immune 
thrombocytopenic purpura of adults and children: report from 
an international working group. Blood 2009;113:2386-93. doi: 
10.1182/blood-2008-07-162503.
[137] O’Leary ST, Glanz JM, McClure DL, Akhtar A, Daley MF, Na-
G.L. D’ALÒ ET AL.
E26
kasato C, Baxter R, Davis RL, Izurieta HS, Lieu TA, Ball R. 
The risk of immune thrombocytopenic purpura after vaccination 
in children and adolescents. Pediatrics 2012;129:248-55. doi: 
10.1542/peds.2011-1111.
[138] Vlacha V, Forman EN, Miron D, Peter G. Recurrent thrombo-
cytopenic purpura after repeated measles-mumps-rubella vac-
cination. Pediatrics 1996;97:738-9.
[139] Drachtman RA, Murphy S, Ettinger LJ. Exacerbation of 
chronic idiopathic thrombocytopenic purpura following mea-
sles-mumps-rubella immunization. Arch Pediatr Adolesc Med 
1994;148:326-7. doi: 10.1001/archpedi.1994.02170030096023
[140] British Committee for Standards in Haematology, Blood Trans-
fusion Task Force. Guidelines for the use of platelet transfu-
sions. Br J Haematol 2003;122:10-23.
[141] Bibby AC, Farrell A, Cummins M, Erlewyn-Lajeunesse M. Is 
MMR immunisation safe in chronic Idiopathic thrombocyto-
penic purpura? Arch Dis Child 2008;93:354-5. doi: 10.1136/
adc.2007.132340.
[142] Moulis G, Lapeyre-Mestre M, Mahévas M, Montastruc JL, Sail-
ler L. Need for an improved vaccination rate in primary im-
mune thrombocytopenia patients exposed to rituximab or sple-
nectomy. A nationwide population-based study in France. Am J 
Hematol 2015;90:301-5. doi: 10.1002/ajh.23930.
[143] World Health Organization. Vaccine safety basics – e-learning 
course. Available at: http://vaccine-safety-training.org/risk-per-
ception.html [Last access: 26/08/2016].
[144] Horowitz J. California governor signs strict school vaccine leg-
islatio“. Associated Press. Retrieved 30 June 2015
[145] Betsch C, Böhm R. Detrimental effects of introducing partial 
compulsory vaccination: experimental evidence. Eur J Public 
Health 2016;26:378-81. doi: 10.1093/eurpub/ckv154.
[146] Austin Bradford H. The Environment and Disease: Association 
or Causation? Proceedings of the Royal Society of Medicine 
1965;58:295-300.
[147] Scherer LD, Shaffer VA, Patel N, Zikmund-Fisher BJ. Can the 
vaccine adverse event reporting system be used to increase 
vaccine acceptance and trust? Vaccine 2016;34:2424-9. doi: 
10.1016/j.vaccine.2016.03.087.
[148] Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Ver-
ger P, Johnston IG, Cook AR, Jones NS. The State of Vac-
cine Confidence 2016: Global Insights Through a 67-Country 
Survey. EBioMedicine 2016;12:295-301. DOI: http://dx.doi.
org/10.1016/j.ebiom.2016.08.042.
n Received on September 9, 2016. Accepted on January 24, 2017.
n Correspondence: Elisabetta Franco, Facoltà di Medicina e Chirur-
gia, Dipartimento di Biomedicina e Prevenzione, via Montpellier 1, 
00133 Roma, Italy. Tel. +39 06 72596122 - Fax +39 06 2025285  - 
E-mail: franco@med.uniroma2.it
